Literature DB >> 1662559

Expression of activated oncogenes in the murine mammary gland: transgenic models for human breast cancer.

W J Muller1.   

Abstract

Breast cancer is the leading cause of death among non-smoking women and thus has been the focus of intensive research. It has been generally accepted that the deregulation of oncogenes or their regulators play a pivotal role in progression of this prevalent disease. For example, amplification and overexpression of a number of oncogenes has been observed in a proportion of primary breast cancer biopsies. More recently, there has also been reports of inactivation tumor suppressor genes in human breast cancer. While there is compelling evidence for a role of these genes in breast cancer tumor progression due to limitations inherent in these studies it is difficult to establish a direct causal association between expression of a certain oncogene and tumor progression. For this reason many groups have employed the transgenic mouse as a model system to directly study effects of oncogene expression in the murine mammary gland. This review will attempt to highlight some of the important lessons and potential applications that have emerged from the study of oncogene expression in the mammary epithelium of transgenic mice. The utility of the transgenic system to assess the transforming potential of oncogenes, to investigate the multi-step nature of malignant progression, and to be used as models for therapeutic intervention will be discussed.

Entities:  

Mesh:

Year:  1991        PMID: 1662559     DOI: 10.1007/bf00050793

Source DB:  PubMed          Journal:  Cancer Metastasis Rev        ISSN: 0167-7659            Impact factor:   9.264


  74 in total

1.  Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer.

Authors:  M J van de Vijver; J L Peterse; W J Mooi; P Wisman; J Lomans; O Dalesio; R Nusse
Journal:  N Engl J Med       Date:  1988-11-10       Impact factor: 91.245

2.  Potential oncogene product related to growth factors.

Authors:  C Dickson; G Peters
Journal:  Nature       Date:  1987 Apr 30-May 6       Impact factor: 49.962

3.  The roles of individual polyoma virus early proteins in oncogenic transformation.

Authors:  M Rassoulzadegan; A Cowie; A Carr; N Glaichenhaus; R Kamen; F Cuzin
Journal:  Nature       Date:  1982-12-23       Impact factor: 49.962

Review 4.  Animal models of human disease. Pathology and molecular biology of spontaneous neoplasms occurring in transgenic mice carrying and expressing activated cellular oncogenes.

Authors:  P K Pattengale; T A Stewart; A Leder; E Sinn; W Muller; I Tepler; E Schmidt; P Leder
Journal:  Am J Pathol       Date:  1989-07       Impact factor: 4.307

5.  Genetic alteration of the c-myc protooncogene (MYC) in human primary breast carcinomas.

Authors:  C Escot; C Theillet; R Lidereau; F Spyratos; M H Champeme; J Gest; R Callahan
Journal:  Proc Natl Acad Sci U S A       Date:  1986-07       Impact factor: 11.205

6.  Development of mammary hyperplasia and neoplasia in MMTV-TGF alpha transgenic mice.

Authors:  Y Matsui; S A Halter; J T Holt; B L Hogan; R J Coffey
Journal:  Cell       Date:  1990-06-15       Impact factor: 41.582

7.  Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome.

Authors:  R Nusse; H E Varmus
Journal:  Cell       Date:  1982-11       Impact factor: 41.582

8.  Amplification of c-erbB-2 oncogene in human adenocarcinomas in vivo.

Authors:  J Yokota; T Yamamoto; K Toyoshima; M Terada; T Sugimura; H Battifora; M J Cline
Journal:  Lancet       Date:  1986-04-05       Impact factor: 79.321

9.  Sequence, topography and protein coding potential of mouse int-2: a putative oncogene activated by mouse mammary tumour virus.

Authors:  R Moore; G Casey; S Brookes; M Dixon; G Peters; C Dickson
Journal:  EMBO J       Date:  1986-05       Impact factor: 11.598

10.  Expression pattern of the FGF-related proto-oncogene int-2 suggests multiple roles in fetal development.

Authors:  D G Wilkinson; S Bhatt; A P McMahon
Journal:  Development       Date:  1989-01       Impact factor: 6.868

View more
  11 in total

1.  In vivo direct molecular imaging of early tumorigenesis and malignant progression induced by transgenic expression of GFP-Met.

Authors:  Sharon Moshitch-Moshkovitz; Galia Tsarfaty; Dafna W Kaufman; Gideon Y Stein; Keren Shichrur; Eddy Solomon; Robert H Sigler; James H Resau; George F Vande Woude; Ilan Tsarfaty
Journal:  Neoplasia       Date:  2006-05       Impact factor: 5.715

Review 2.  The comparative pathology of human and mouse mammary glands.

Authors:  R D Cardiff; S R Wellings
Journal:  J Mammary Gland Biol Neoplasia       Date:  1999-01       Impact factor: 2.673

Review 3.  The biology of mammary transgenes: five rules.

Authors:  R D Cardiff
Journal:  J Mammary Gland Biol Neoplasia       Date:  1996-01       Impact factor: 2.673

4.  Targeting tumor vasculature with novel Listeria-based vaccines directed against CD105.

Authors:  Laurence M Wood; Zhen-Kun Pan; Patrick Guirnalda; Peter Tsai; Matthew Seavey; Yvonne Paterson
Journal:  Cancer Immunol Immunother       Date:  2011-03-23       Impact factor: 6.968

5.  Cancer immunotherapy targeting the high molecular weight melanoma-associated antigen protein results in a broad antitumor response and reduction of pericytes in the tumor vasculature.

Authors:  Paulo Cesar Maciag; Matthew M Seavey; Zhen-Kun Pan; Soldano Ferrone; Yvonne Paterson
Journal:  Cancer Res       Date:  2008-10-01       Impact factor: 12.701

Review 6.  Genetically engineered mouse models of mammary intraepithelial neoplasia.

Authors:  R D Cardiff; D Moghanaki; R A Jensen
Journal:  J Mammary Gland Biol Neoplasia       Date:  2000-10       Impact factor: 2.673

7.  Distinct effects of the mesenchymal dysplasia gene variant of murine Patched-1 protein on canonical and non-canonical Hedgehog signaling pathways.

Authors:  Malcolm C Harvey; Andrew Fleet; Nadia Okolowsky; Paul A Hamel
Journal:  J Biol Chem       Date:  2014-02-25       Impact factor: 5.157

8.  Transgenic mice expressing a dominant-negative mutant type II transforming growth factor-beta receptor exhibit impaired mammary development and enhanced mammary tumor formation.

Authors:  Agnieszka E Gorska; Roy A Jensen; Yu Shyr; Mary E Aakre; Neil A Bhowmick; Harold L Moses
Journal:  Am J Pathol       Date:  2003-10       Impact factor: 4.307

9.  Cancer immunotherapy using Listeria monocytogenes and listerial virulence factors.

Authors:  Laurence M Wood; Patrick D Guirnalda; Matthew M Seavey; Yvonne Paterson
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

Review 10.  Preclinical models for the evaluation of targeted therapies of metastatic disease.

Authors:  S A Eccles; G Box; W Court; J Sandle; C J Dean
Journal:  Cell Biophys       Date:  1994
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.